US FDA panel reviews set for asthma agents Xolair and Aridol
29 September 2009
Sue Sutter
sue.sutter@informa.com
The US
FDA's pulmonary-allergy drugs advisory panel will meet on November 18th to consider extending the use of
Roche (formerly Genentech)/
Novartis's humanised monoclonal antibody Xolair (omalizumab) to younger children with asthma.
Separately, the panel will review an asthma diagnostic...
Please Login to read the full article.